3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
2
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Endocrine
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
137
Parkinson Disease 4, Autosomal Dominant Lewy Body
124
Melanoma
95
Neoplasms
75
Squamous Cell Carcinoma of Head and Neck
65
Colorectal Neoplasms
42
Triple Negative Breast Neoplasms
38
Carcinoma, Renal Cell
37
Lung Neoplasms
36
Head and Neck Neoplasms
34
Breast Neoplasms
34
Stomach Neoplasms
33
Urinary Bladder Neoplasms
32
Neoplasm Metastasis
32
Carcinoma, Hepatocellular
32
Pancreatic Neoplasms
30
Ovarian Neoplasms
29
Carcinoma, Transitional Cell
25
Endometrial Neoplasms
19
Recurrence
16
Sarcoma
15
Esophageal Neoplasms
15
Carcinoma
15
Uterine Cervical Neoplasms
14
Prostatic Neoplasms
14
Small Cell Lung Carcinoma
13
Lymphoma
13
Fallopian Tube Neoplasms
13
Carcinoma, Squamous Cell
13
Lymphoma, Non-Hodgkin
12
Interventions
Paclitaxel
5
Etoposide
4
Oxaliplatin
3
Ifosfamide
3
Granulocyte Colony-Stimulating Factor
3
Gemcitabine
3
Cyclophosphamide
3
Cisplatin
3
Carboplatin
3
ribociclib
2
fludarabine
2
etoposide phosphate
2
Stem Cell Transplantation
2
Sirolimus
2
Melphalan
2
Filgrastim
2
Everolimus
2
Busulfan
2
130-nm albumin-bound paclitaxel
2
trametinib
1
tozuleristide
1
sonidegib
1
ripretinib
1
pralsetinib
1
pembrolizumab
1
pegylated granulocyte colony-stimulating factor
1
pegfilgrastim
1
pazopanib
1
olaparib
1
interferon gamma-1b
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neoplasms, Germ Cell and Embryonal
×
pembrolizumab
×
Clear all
NCT03012620
2024-02-28
AcSé
UNICANCER
Phase 2
Completed
334 enrolled